



Geographical difference of chromosome aberrations between Japanese and American small cell lung cancer cell lines

Kimio Tanaka^{1*} and Takahiko Sakuma²

¹Department of Radiobiology, Research Institute for Environmental Sciences, Hachazawa 2-121, Takahoko, Rokkasho, Kamikita, Aomori 039-3213, Japan

²Department of 4th Internal Medicine, Center for Adult Diseases, Nakamichi 1-3-2, Higashinari-ku, Osaka 734-8552, Japan

kmtanaka@ies.or.jp*

Abstract

Lung-cancer is the leading cause of cancer-related death worldwide. Cytogenetic analysis have been performed last two decades, but comparative analysis of karyotypes of small cell lung cancer (SCLC) from between Japan and America has not been precisely studied. Six Japanese and one American SCLC cell lines examined were hyperdiploid to neartetraploid with modal number of 52-91. These cells had a complex karyotype with more than 10 rearrangements. The karyotypic patterns were relatively consistent alterations involved long arm of chromosomes 1, 3, 7 and 11, and short arm of chromosomes 1 and 3. Higher rearrangements specially associated with translocations and deletions were observed in short and long arms of chromosomes 3 (3p21 & 3q25), and recurrently long arms of chromosome 7 (7q36 and 7q23). Although the chromosome of SCLC is too complex and G-banding analysis could not resolve all of many of the karyotypic abnormalities seen, several potentially site -specific abnormalities such as deletions of chromosome 3p, 7q and 3q, and amplifications of 3p, 7q, 1q, 11p, 2p and 12p in 6 SCLC cell lines established from chemotherapy resistant patients tumor cells. Losses of short arm chromosome 11 and 12 (11p, 12p) and long arm of chromosome 13 (13q), and amplifications of chromosomes 2, 11, 12, 13 and 19 (2p, 11p, 12p, 13q, 19p) were recurrently identified in the several cell lines, being different from published chromosomal abnormalities in American SCLC, which suggests geographical difference of SCLC karyotype. Also, these abnormal patters were largely different from non-small cell lung carcinoma (NSCLC). Unknown oncogenes localizing on these chromosome breakpoints for translocation or deletion region might be associated with the pathogenesis of SCLC. Present analysis can provide information on significant genes involved pathogenesis of SCLC.


Keywords: Chromosome aberration, lung cancer.

Introduction

Lung cancer is the leading cause of cancer death in Japan and worldwide, accounting for over 4931 deaths in 1975-1977 in Japan alone (Yoshimura & Yamashita 1982). Clinical statistical analysis according to histological type was performed. Lung cancer can be histologically sub-classified into 4 major categories: squamous cell carcinoma (epidermoid carcinoma), lung adenocarcinoma, and undifferentiated large cell carcinoma, comprising non-small cell lung cancer (NSCLC), and undifferentiated small cell carcinoma (SCLC). Epidermoid carcinoma accounted for 46.6% of male cases and 18.8% in female cases, while adenocarcinoma was 61.2% of female cases and 30.3% in male cases in Japan. SCLC accounted for 11.5% in male cases and 8.3% in female cases. Squamous carcinoma was predominant in male, and male and female sex ratio was 8:1, but lung adenocarcinoma was higher in female. 5- year survival rates were 14.4%, 14.4%, 11.9%, 5.4% and 1.3% for epidermoid carcinoma, adenocarcinoma, large cell carcinoma, small cell carcinoma intermediated cell type and oat cell type, respectively (Yoshimura & Yamashita, 1982). SCLC has poor prognosis and remains from target therapy.

Although the squamous cell carcinomas are most common, the majority of the lung tumors so far cytogenetically investigated have been the small- cell type. Whang-Peng have reported a very specific chromosome abnormality, del(3)(p14p23) in SCLC (Wang-Peng *et al.*, 1982). The segment 3p14-3p23 always seems to be part of the lost region for common deleted regional segments, when the breakpoints were different among authors (Miura *et al.* 1992). RFLP analysis of 3p markers confirmed almost universal loss of the region (Bauch *et al.*, 1987). Deletions and other rearrangements involving short arm of chromosome 3 (3p) have been also reported previously in several NSCLC tumors and cell lines (Zech *et al.*, 1985; Jin *et al.*, 1988; Bello *et al.*, 1989; Miura *et al.*, 1990a, b; Testa *et al.*, 1994). Therefore, the del(3)(p14p23) is well established as a specific marker for SCLC and NSCLC of lung cancers. It is found predominantly in SCLC, but it has been present in only some cases or nearly all NSCLC cases examined. More data are needed on other chromosome abnormalities before the prevalence of deletion of short arm of chromosome 3(3p-) in SCLC tumors and other histological type tumors.

Fig. 1. Chromosome breakpoints related to structural chromosome aberrations in 6 Japanese SCCL cell lines and an American SCLC cell line and reference cases*



X : Japanese 6 SCLC cell lines ● : An American SCLC cell line, - : References

Chromosome abnormalities are a common in these tumor cells, which will be a good clinical and biological indicator as well as suitable indicator to reveal new, recurrent oncogene changes relevant to development of these cancers. Molecular events in the carcinogenesis of these cancers remain, although a few relevant genes such as *Tp53*, *RB*, *STK11*, *EGFR* and *CDKN2A* in lung cancer have been identified (Greulich 2011). Established cancer cell lines will be useful for isolating oncogenes as well as for cellular changes relating to tumor pathogenesis and progression. Geological difference of tumor karyotype has been observed in leukemias and lymphomas, but comparative karyotype analysis between

Japanese and American SCLC cases has not been performed. In this report, we describe the establishment of these cell lines and detailed karyotypes of seven SCLC cell lines. Although the karyotype in SCLC appeared to be very complex, several specific and recurrent abnormalities and breakpoint cluster sites have been identified that should be helpful to focus further molecular investigation. Present analysis revealed a possibility that karyotype of SCLC is geographically different.

Materials and methods

Cell lines

Six Japanese lung cancer cell lines (K#1-1-1, NKM, HT, SWD, OHf, FJt) were established from plural fluid of 54 to 71-year-old Japanese male or female patients with SCLC. For comparison, one female cell line (M417) was established from 66 year- old American SCLC patient. These seven patients whose samples were used for establishing cell line had been received chemotherapy using cyclophosphamide, vincristine, adriamycin, etoposide and vincdesine. The original tumor specimens obtained at stage after the therapy or at metastasis stage were initiated for establishing cell lines. These cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1.2% L-glutamine, and 0.8% streptomycin. One half of the medium was replaced with fresh medium twice each week. Sub-cultivation was performed once every two weeks. Cells were examined cytogenetically at passage 20 to 80 of these cell lines.

Cytogenetic analysis

Cells in exponential growth after set up culture with fresh medium for 20-48h were exposed to colcemid (0.02 ug/ml) for 1 h to arrest adequate number of mitoses for karyotypic examinations. The cells were removed from the surface of the flask by trypsinization and then exposed to hypotonic solution consisting of a 1:4 mixture of 1% sodium citrate and 0.075 M KCl for 30 minutes. The cells were fixed with a 3:1 mixture of methanol/acetic acid. Metaphases analyzed were examined using trypsin G-banding techniques. One American cell line (M417) was stained by Q-banding. Chromosome counts were performed on 15-35 metaphase plates. Karyotypes were analyzed from 12-15 well spread, banded metaphase chromosomes. Chromosomes were identified according to the

Fig. 2. A representative G-banded karyotype of K#1-1-1 cell line established at metastasis stage from a SCLC patient. Marker chromosomes are shown as mar. Arrow indicates abnormal chromosomes.





Fig. 3. A representative G-banded karyotype of HT cell line established at metastasis from a SCLC patient. Marker chromosomes are shown as mar. Arrow indicates abnormal chromosomes.



International System for Human Cytogenetic Nomenclature (ISCN2005).

Results

SCLC cell lines

We reported the establishment and cytogenetic characterization of 6 Japanese SCLC cell lines and one American SCLC cell line derived from human metastasis lung tumors, and compared their properties of chromosome aberrations. These all cell lines were grown as single, non-organized layers, similar to fibroblasts with

former formation, heterogeneous cell division, and cell cycle approximately 20-38 h.

All cell lines were characterized not only by numerical aberrations but also by structural rearrangements affecting various chromosomes. In Japanese 6 cell lines, the modal chromosome numbers found to be in the hypotriploid to hypertriploid ranging between 51 and 91. Most cells at this passage were hyper-diploid with modal number of 52, 51 and 62 in 3 cell lines (k#1-1-1, NKM, SWD), and near triploid with a modal chromosome number of 69 and 74 in 2 cell lines (HT, OHf). Distribution of chromosome breakpoints in 6 Japanese cell lines is shown in Fig.1. Fig. 2, 3 and 4 show G-banded representative karyotypes of these cell lines (K#1-1-1, HT and OHf, respectively). In K#1-1-1 cell line (Fig.2), six structurally rearranged chromosomes were constantly identified in most cells. The karyotype had add(2), add(6), der(12)t(2;12), add(13)(q14) and 2-3 marker chromosomes.

In HT cell line (Fig.3), the chromosome pattern showed slight variation from cell to cell, and twelve structurally rearranged chromosomes were constantly identified in most cells. Another six markers were found in 20-64% of the metaphases. The karyotype of this cell line contained rearrangements of add(2), two kinds of der(3), add(3), two kind of add(6), add(7), add(8), add(9), add(11), add(12) and 2 double minute (dim) accompanying loss of chromosomes 2, 7, 15 and 22 lost from neartriploid range.

In OHf cell line (Fig.4), eighteen structurally rearranged chromosomes were constantly identified in most cells. Figure 4 shows G-banded representative karyotypes of the cell line. Another 15 markers were found in about 30-80 % of metaphases. The karyotype of this cell line contained der(1), add(1), add(3), add(4), del(5), der(7), add(8), add(11), del(11), another add(11), add(12), del(12), add(14) and add(?17), accompanying loss of 4, 13, 14, 15, 17, 19, 21 and 22 lost from near-tetraploid range. The cell line had also one homogenous staining region (HSR) at 7q36-7q25 region of the der(7) chromosome.

In an American SCLC cell line (M417), (Fig.5), ten rearranged chromosomes such as add(1), t(3;7;?), der(4)t(?3;4), add(?9), add(11) and der(21)t(?7;22) were identified constantly, which karyotype is shown in Fig.5.

Fig. 4. A representative G-banded karyotype of OHf cell line established at metastasis from a SCLC patient. Marker chromosomes are shown as mar. Arrow indicates abnormal chromosomes.





Fig. 5. A representative Q-banded karyotype of M417 cell line established at metastasis from an American SCLC patient. Marker chromosomes are shown as mar. Arrow indicates abnormal chromosomes.



This cell line had an abnormality on chromosome 3p similar to Japanese SCLC, but not on chromosome 7q.

Whole karyotypes of these 7 cell lines are listed in Table 1. In important, several types of short arm or long arm of chromosome 3 rearrangements such as $der(3)t(3;7)$, $der(3)t(3;19)$, $der(3)t(?;3;?)$, $add(3)(q25)$, $add(3)(p13)$, $add(3)(p11)$ and $t(3;7;?)$ were predominantly found to all 7 cell lines established, although the breakpoints were variable from 3p21, 3p13, 3p11, 3q12, 3q21 and 3q25 (Fig.1), which is shown in bold letter in

Table 1. Our interpretation of the origin of the associating several derivative chromosomes is presented in Table 1. In secondly higher incidence, derivative abnormalities of chromosome 7 at breakpoint at 7q36 such as $add(7)(q36)$, $der(7)t(?;7;?)$, $der(7)t(7;?;7)$, $add(7)$ and $t(3;7;?)$ were observed in 5 cell lines (Fig.1), (4 Japanese and one American cell lines), which are shown in underlined in Table 1. Only one cell line (OHf) had HSR chromosome 7 and only one cell line (HT) had dmin chromosomes.

In an American SCLC cell line (M417), ten rearranged chromosomes such as $add(1)$, $t(3;7;?)$, $der(4)t(?3;4)$, $add(?9)$, $add(11)$ and $der(21)t(?;7;22)$ were identified constantly. This cell line had an abnormality on short arm of chromosome 3 (3p) similar to other Japanese SCLC cell lines, but not on long arm of chromosome 7 (7q).

Gains of whole chromosome were higher found in chromosomes 2 and 6 and losses of whole chromosome were slightly higher in chromosomes 1, 3, 19, 21 and 22 (Table 2). Structural chromosome abnormalities such as deletion, derivative chromosome and additional chromosomes were frequently observed in short arm of chromosomes 1 and 3 (designated as 1p and 3p, respectively), and long arm of chromosomes 1, 3, 4, 7 and 8 (designated as 1q, 3q, 4q and 8q, respectively) (Table 3). Common deleted regions of 3p15-pter, 7q36-qter, 3q25-qter, 8q24-qter and 11p15-pter were seen in 7, 7, 4, 3 and 3 cell lines. Common amplified regions were found at 3p13-3q21 in 15 copies, 7q11-7q22 in 12 copies each, 1q11-qter and 11p15-q21 in 8 copies each, 12p11.2-qter and 6p23-qter in 6 copies each, and 4pter-4q35, 4p13-pter, 13pter-q14, 4q21-qter in 4 copies each in 8 cell lines, in which number of copy was counted including normal chromosomes. Thus the most affected chromosome bands were 7q36 of chromosome 7, 3q25 of chromosome 3, 3p13 of chromosome 3, 7q32, 4q31, 5q13 and 8q24.3 (Fig. 1).

Discussion

The establishment of SCLC cell lines can facilitate the search for mechanism underlying its pathogenesis. These newly established cell lines will be useful tools in the study of the molecular pathogenesis and biological behavior of these cancer cells and for testing new therapeutic reagents for these cancers in the future. Though lung cancer is common in the world, but almost no comparative study on karyotype using chromosomal banding studies between Japanese and American cases have been reported. A karyotype study on American 6

Table 1. Karyotypes of 7 SCLC cell lines established

Cell lines	Composite Karyotypes (chromosome aberrations found in several side clones)
K#1-1-1	50-57, X, +X, add(Y)(q12), add(2)(q31), der(3)t(3;7)(p21;q11) , -4, del(4)(q21q31), +add(6)(q13), der(12)t(2;12)(q13;p13), add(13)(q14), +21, +22, +22, +mar1,+mar2,+mar3 [4]
NKM	58-73, XY, add(1) (q25), add(1) (q12), +add(1) (p13),+add(1)(p22), +add(1)(p11), +del(2)(p21), der(3)t(3;19)(q25;p13)x2 , add(3)(q25) , +add(3)(q23) , +6, add(8)(q22), +der(8)t(?5;8)(?q13;q13),+add(9)(p22), add(11)(q23), -13, +del(13)(?q2?q14)x2, +15, -19, -20, -21, +mar1. +mar2,+mar3,+mar4,+mar5,+mar6,+mar7 [6]
HT	56-69, XY, +X, +1,-2, add(2)(?p13), der(3)t(?;3;?) (?::p13-cent-q25::?) , +der(3) t(?;3;?) (?::p25-cen-q27::?) , +add(3)(q25) , +add(6)(q21), +add(6)(p23), -7, <u>add(7)(q36)x2</u> , +8, +add(8)(q24.3), add(9)(p22), +10,+10, add(11)(p13), +12, +add(12)(p11.2), -15, +16, +17, +18, add(20)(p13), -22, +mar1, +mar2, +mar3, +mar4,+mar5, +mar6, +mar7,+2dim [9]
SWD	47-54, XY, add(1)(q12),-2, +add(1)(q11), +add(1)(q11), add(3)(q25) , +add(3)(p13) , add(4)(q31), der(4)t(?;4;?) (?;q31;?), add(4)(q31), -5, <u>del(7)(p15-cen-q23)</u> , add(6)(q15), <u>add(7)(q36)</u> , <u>der(7)t(?;7;?) (?;q36;?)</u> , add(8)(q24), -9, add(9)(q22), der(11)t(11;12)(p11.2;q11),+i(11)(p10), -12, add(12)(p11.2), -13, -17, +18, -19, +21, -22, -22, +mar1, +mar2, +mar3, +mar4, +mar5, +mar6 x2, +mar7,+mar 8 [10]
OHf	75-82, XX, der(1)t(?;1;?) (?::p11.2-cen-q44::?), add(1)(p36.1), +2, +add(3)(p11) , -4, +add(4)(q35)x2, +del(5)(q31)x2, +6,+6, +7, <u>der(7)t(7;7;?) (q36,HSR;q25)</u> , add(8)(q24.3), +10, +add(11)(q23)x2, +del(11)(q23), +add(11)(q21)x2, add(12)(p11.2), +del(12)(p13), -13, -14, add(14)(q32), -15, -17, add(?17)(?q21), +18, -19, +20, -21, -22, -22, +mar1, +mar2, +mar3, +mar4, +mar5,+mar6, +mar7,+mar8, +mar9, +mar10, +mar11, +mar12, +mar13, +mar14, +mar15 [8]
FJt	88-95, XY, +X, +add(1)(q21), +add(1)(q23), +2, +2, +3,+add(3)(p11) , +add(3)(p13)x2 , +4, +5, +6, +del(6)(q21), +7, <u>add(7)(q32)</u> , +add(8)(q24.3), +11, +add(11)(p15), +12, +13, +14, +add(14)(q32), +15, +15, +17, +18, -19, -21, +mar1, +mar2, +mar3, +mar4, +mar5,+mar6, +mar7,+mar8, +mar9, +mar10, +mar11, +mar12, +mar13, +mar14, +mar15, +mar16 [7]
M417 *	53, X, -X, +add(1)(q42), t(3;7;?) (pter-?p21::?q36-?p13::?) , der(4)t(?3;4)(pter-p21::qter-p14), +7, add(?9)(pter-q?11), +add(11)(p14), add(15)(q22), +der(17)t(?5;17)(?p11;p11), +der(19) t(?7;19) (pter-?p13::qter-p23), +21, der(21)t(?7;21)(?q11-qter:pter-?q13)

*American SCLC cell line; Bold: abnormalities on chromosome 3p; underlined: abnormalities on chromosome 7q

fresh patients and 7 cell lines with SCLC showed hypodiploidy to neartetraploidy with modal numbers of 38-78, no normal chromosomes of 17, 21 and 22 in each one case, and structural rearrangements of chromosomes 3, 17 and 13 as well as complex alteration (Miura *et al.*, 1992). In addition, the tumors and cell lines had structural chromosome aberrations such as deletion of chromosome 3p in 13 cases, add(17)(p13) in 12 cases, rearrangement at 13q14 of chromosome 13 in 10 cases and alteration of chromosome 5q in 12 cases, which were also found in our present analysis except 17p13 and 13q14 abnormalities (Fig.1 and Table 1). For comparison, an American cell line (M417) and published samples from reference no 24 (Mimura *et al.*, 1992) are shown in Fig. 1.

More accurate analysis using array comparative genomic hybridization (CGH) revealed that decrease DNA copy number on 3p, 5q, 10, 16q and 17p, and frequent gain of DNA copy number on 3q, 1p, 1q and 14q (Ashman *et al.*, 2002), and loss of regions implicated regions being 3p13-14, 4q32-35, 5q32-35, 8p21-22, 10q25, 13q13-14, and 17p12-13, and common gains include regions being 3q26-29, 5p12-13, 8q23-24 and 19p13.1 (Heiway & Betticher, 2004).

Loss of 5q region by CGH was coincident with highly observed isochromosome 5p or deletion of chromosome 5q in SCLC (Miura *et al.*, 1992; Hartel *et al.*, 2008). In comparison with American cases, present Japanese cell lines showed different results, which

Table 2. Number of numerical chromosome aberrations in each chromosome in Japanese 6 SCLC cell lines (Italic letters show chromosome number. Bold letters show higher number of aberrations.)

Chromosome Gain																							
1	4	1	1	2	5	2	1	0	3	1	2	2	1	3	1	2	3	0	1	1	2	0	0
<i>1</i>	<i>2</i>	<i>3</i>	<i>4</i>	<i>5</i>	<i>6</i>	<i>7</i>	<i>8</i>	<i>9</i>	<i>10</i>	<i>11</i>	<i>12</i>	<i>13</i>	<i>14</i>	<i>15</i>	<i>16</i>	<i>17</i>	<i>18</i>	<i>19</i>	<i>20</i>	<i>21</i>	<i>22</i>	<i>X</i>	<i>Y</i>
3	2	3	1	0	0	2	2	1	0	2	2	2	2	2	0	2	0	3	1	3	3	0	0
Chromosome Loss																							

Table 3. Number of breakpoints related to structural chromosome aberrations in each chromosome in Japanese 6 SCLC cell lines (Italic letters show chromosome number. Bold letters show higher number of aberrations.)

Short arm of chromosome																							
6	2	7	0	0	2	1	1	2	0	4	4	0	0	0	0	0	0	1	0	0	0	0	0
<i>1</i>	<i>2</i>	<i>3</i>	<i>4</i>	<i>5</i>	<i>6</i>	<i>7</i>	<i>8</i>	<i>9</i>	<i>10</i>	<i>11</i>	<i>12</i>	<i>13</i>	<i>14</i>	<i>15</i>	<i>16</i>	<i>17</i>	<i>18</i>	<i>19</i>	<i>20</i>	<i>21</i>	<i>22</i>	<i>X</i>	<i>Y</i>
9	3	7	6	1	4	13	6	1	0	5	3	3	2	0	0	0	0	0	0	0	0	0	0
Long arm of chromosome																							

had hyper-diploid to neartetraploidy modal number and higher abnormalities on chromosome 3p, 3q and 7q, slightly higher in 5q, but no abnormalities on 13q14 and 17p13. In addition, out of 6 Japanese cell line, only one cell line had HSR and dmin chromosomes independently, while in the American SCLC cases, abnormal banded region (ABR), HSR and dmin were more observed in 4 of 13 cases observed (31%) (Miura *et al.*, 1992). Therefore, there is a possibility that cytogenetic features in SCLC might be different between western and oriental countries.

Chromosome breakpoint regions formed with a translocation, deletion and amplification are considered to be containing recurrent oncogene associated with pathogenesis or progression of SCLC. Present study suggests that the breakpoint regions of 3p13, 3q26 and 7q36, and also deletion regions of 1q44-qter, 6q21-qter, 8q24.3-qter, 11p15-pter, 12p13-pter and 13q14-q22? might have important genes for pathogenesis of SCLC. These chromosomal breakpoints associated with deleted or amplified regions might contain identified genes of *FHIT*, *RASSF1* and *FUS1* at 3p13 (Zabarvsky *et al.*, 2002), *MDR/ABC1* and *MET* on chromosome 7 (Yabuki *et al.*, 2007; Engelman *et al.*, 2007), *MYC* at 8q24.3 and *RB1* at 13q14 (Rygaard *et al.*, 1990; Yuan *et al.*, 1999), so the study on whether these oncogenes are associated with SCLC will be needed. No oncogene has been identified on 12p13, but amplification and over expression of *DYRK2* gene at 12q14 in lung adenocarcinoma has been reported (Miller *et al.*, 2003). Then currently developed array CGH such as single nucleotide polymorphism (SNP) microarray on SCLC also detected small deleted region involving *RB1(RB)* and *CDKN2A(p16)*, (Nagayama *et al.*, 2007) and chromosomal amplifications of 1p36.1 containing *WNT4* (Garnis *et al.*, 2005), of 5p13 of chromosome 5 involving *SKP2* (Coe *et al.*, 2005; Yokoi *et al.*, 2009), of chromosome 2 involving *ABC1* (Kitada *et al.*, 2009) and *TERT* of chromosome 18q (Salido *et al.*, 2009) and of 22q1.21 of chromosome 22 containing *CRKL* (Kim *et al.*, 2010).

Further, small size regions associated with gene deletion and amplification could be detected by array CGH, not G-banding analysis. The affected regions of 3q26, 7q36 of chromosome 7 and of 12p11.2 of chromosome 12 have also been recurrently observed in SCLC, which had also been observed in NSCLC (Lee *et al.*, 1987; Miura *et al.*, 1990a, 1990b; Testa *et al.*, 1994), esophagus cancer and ovarian cancer, stomach cancer, and breast cancer and seminoma. Array CGH analysis revealed that copy number alteration at 3q27.1 highlighted the connection of *THPO*, *SOX2* and *PIK3CA* novel oncogene activation at 3q27 and tumor cell growth in NSCLC (Baik *et al.*, 2009; McCaughan *et al.*, 2010). Less frequent gain of copies of chromosomal region such as 7q22.3-31.31 and 12p11.23-13.2 in NSCLC identified by CGH analysis (Dehan *et al.*, 2007), being different

from present karyotype results on SCLC, which are implying that chromosome patterns of NSCLC and SCLC are different. Genome-wide high resolution analysis also suggested that SCLC and NSCLC had different specific genetic alterations and expressions (Girard *et al.*, 2000; Wistuba *et al.*, 2001).

The etiology of SCLC is strongly tied to cigarette smoking. And then, more than 80% of lung cancers are attributed to tobacco exposure. However, since only a fraction of long-term smokers of about 15% will develop lung cancer in their life time, it is proposed that genetic factors play a role in individual susceptibility (Sheilds 2002). All SCLC patients, whose tumor specimens were used for establishing present cell lines, had severe resistance to chemotherapy. Levels of gultathione S-transferase (*GST-P*) correlate with the resistance to cisplatin and carbolation in human cancer cell line (Wakagawa *et al.*, 1988). Similar finding was observed in our 6 Japanese cell lines examined. *GSTs* are family of enzymes that detoxify hydrophobic electrophiles that have been implicated in the pathogenesis of lung cancer. *GST* related genes mapped on chromosomes 1p36.1, 1p31, 6p12.2, 8p21.1 and 12q13-q14. No correlation between resistance to chemotherapy in the patients and chromosome deletions and amplifications on these region involving *GST*-related genes were observed in these 6 Japanese cell lines. These drug-resistant lung cancer cell lines has an increased copy number in the *MDR1/ABC1* locus region on 7q32 of chromosome 7 and significantly higher number or chromosome 7 alterations (Slovak *et al.*, 1987; Ueda *et al.*, 1986; Yabuki *et al.*, 2007). The presence of recurring chromosome 7 alterations did not always contain oncogenes *EGFR* at 7q11.2 and *MET* at 7q31.2 in NSCLC having amplified chromosome 7. Other genes such as *FTSJ2*, *NUDT1*, *TAF6* and *POLR2J* were identified as candidate gene on chromosome 7 associated with drug-resistant (Campbell *et al.*, 2008).

Since variant SCLC cells have a less differentiated neuroendocrine phenotype than their classic counterparts, it was of interest to examine the effects of a differentiation inducer such as retinoic acid and vitamin A on variant and classical SCLC. Expression of retinoic acid α (*RAR α*), retinoic acid β (*RAR β*) and retinoic acid γ (*RAR γ*) was examined SCLC cell line (Martin *et al.*, 1990). Variant SCLC is distinguished from classic histology by changing growth rate, morphology, *MYC* amplification, a loss of some biochemical markers and some chemo-and radio resistance. The variant SCLC grows and leads a morphological change after exposure to retinoic acid, similar to classical SCLC (Doyle *et al.*, 1989). No correlation between differentiation to *RARs* in the patients and chromosome deletions and amplifications on these regions involving *RAR α* , *RAR β* and *RAR γ* genes were observed in these 6 Japanese cell lines.

Current techniques of M-FISH analyses, gene expression array, methylation-specific PCR, whole DNA sequencing of cancer cell lines and tumors will reveal more important genetic changes such as disease specific translocations for lung cancers affecting chromosomes sites that harbor genes known to pathogenesis in tumorigenesis and progression of human neoplasias (Inamura & Ishikawa 2007; Meiju *et al.*, 2011), which will be therapeutic targets for cancer chemoprevention.

Acknowledgments

We thank Prof. Miura I. of St. Marianna University of School of Medicine for important comments and Prof. Resau J. of Maryland Cancer Center for providing tumor samples. The study was supported in part by Grants-in Aid for Scientific Research from Ministry of Education, Culture, Sports, Science and Technology of Japan (K.T).

References

1. Ashman JN, Brigham J, Cowen ME, Greenman J, Lind M and Cawtkwell L (2002) Chromosomal alterations in small cell lung cancer revealed by multicolour fluorescence *in situ* hybridization. *Int. J. Cancer*. 102(3), 230-236.
2. Baik SH, Jee BK, Choi JS, Yoon HK, Lee KH, Kim YH and Lim Y (2009) DNA profiling by array comparative genomic hybridization (CGH) of peripheral blood mononuclear cells (PBMC) and tumor tissue cell in non-small cell lung cancer (NSCLC). *Mol. Biol. Rep.* 36(7), 1767-1778.
3. Bauch H, Johnson B, Hovis J, Yano T, Gazdar A, Pettengill OS, Grasizano S, Sourenson GD, Poiesz BJ, Minna J, Linehan M and Zbar B (1987) Molecular analysis of the short arm of chromosome 3 in small-cell and non-small cell carcinoma of the lung. *N. Engl. J. Med.* 317, 1109-1113.
4. Bello MJ, Moreno S and Rey JA (1989) Involvement of chromosomes 1, 3 and i(8q) in lung adenocarcinoma. *Cancer Genet. Cytogenet.* 38, 133-135.
5. Coe BP, Henderson LJ, Garnis C, Tsao MS, Minna J, Lam S, Macaulay C and Lam WL (2005) High-resolution chromosome arm 5p array CGH analysis of small cell lung carcinoma cell line. *Genes Chrom. Cancer*. 42(3), 308-331.
6. Dehan E, Be-Dor A, Liao W, Lipson D, Frimer H, Rienstein S, Simansky D, Krupsky M, Yaron P, Friedman E, Rechavi G, Perlman M, Aviram-Goldring A, Izraeli S, Bittner M, Yakhini Z and Kaminski N (2007) Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. *Lung Cancer*. 56, 175-184.
7. Doyle AL, Giangiulo D, Hussain A, Park H-J, Chiu Yen R W and Borges M (1989) Differentiation of human variant small cell lung cancer cell lines to a classic morphology by retinoic acid. *Cancer Res.* 49, 6745-6751.
8. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Oh Park J, Linderman N, Gale Ch-M, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers A, Cappuzzo F, Mok T, Lee Ch., Johson B, Cantley LC and Ja'ne PA (2007) *MET* amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Sci.* 316, 1039-1043.
9. Garnis C, Campbell J, Davies JJ, Macaulay C, Lam S and Lam WL (2005) Involvement of multiple developmental genes on chromosome 1p in lung tumorigenesis. *Hum. Mol. Genet.* 14(4), 475-482.
10. Girard L, Zöchbauer-Müller S, Virmani AK, Gazdar AF and Minna JD (2000) Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. *Cancer Res.* 60(17), 4894-4906.
11. Greulich H (2011) The genomics of lung adenocarcinoma: opportunities for targeted therapies. *Genes & Cancer.* 1(12), 1200-1210.
12. Hartel PH, Shackelford AL, Hartel JV and Wenger SL (2008) Del (5) is associated with clinical and histological parameters in small cell neuroendocrine lung carcinoma. *Int. J. Sug. Pathol.* 16(4), 419-423.
13. Heiway J and Betticher DC (2004) Lung : small cell cancer. *Atras Genet Cytoget Oncol Haematol.* June, 2004.
URL:<http://AtlasGeneticsOncology.org/Tumors?LungSmallCellID15142.html>
14. Inamura K and Ishikawa Y (2007) Microarray analysis for detection of metastasis and evaluation of prognosis in lung cancers. *Jap. J. Lung Cancer.* 48(4), 247:253.
15. ISCN (2005) An International System for Human Cytogenetic Nomenclature. Shaffer LG & Tommerrup N (ed.), also in *Cytogenetics & Genome Res.* Karger, Basel.
16. Jin YS, Mandahl N, Heim S, Schüller H and Mitelman F (1988) Isochromosomes i(8q) or i(9q) in three adenocarcinomas of the lung. *Cancer Genet. Cytogenet.* 33(1), 11-17.
17. Kim YH, Kwei KA, Salari K, Kao J, Pacyna-Gengelbach M, Wang P, Hernandez-Boussard T, Gazdar AF, Petersen I, Minna JD and Pollack JR (2010) Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. *Oncogene.* 29(10), 1421-1430.
18. Kitada K, Yamasaki T and Aikawa S (2009) Amplification of the ABCB1 region accompanied by a short sequence of 200 bp from chromosome 2 in lung cancer cells. *Cancer Genet. Cytogenet.* 194(1), 4-11.
19. Lee JS, Pathak S, Hopwood V, Tomosovic B, Mullins TD, Baker FL, Spitzer G and Neidhart JA (1987) Involvement of chromosome 7 in primary lung tumor and nonmalignant normal lung tissue. *Cancer Res.* 47, 6349-6352.
20. Martin CA, Ziegler LM and Napoli JL (1990) Retinoic acid, dibutyl-cAMP, and differentiation affect the expression of retinoic acid receptors in F9 cells. *Proc.*

- Natl. Acad. Sci, USA.* 87, 4804-4808.
21. Meiju Ji, Haixia G, Cuixia G, Bingyn S and Peng H (2011) Highly frequent promotor methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). *BMC Cancer* 11:147, doi: 10.1186/1471:2407:11:147.
 22. McCaughan F, Pole JC, Bankier AT, Konforov BA, Falzon M, Rabbitts TH, George PJ, Dear PH and Rabbitts PH (2010) Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung. *Am. J. Respir. Crit. Care Med.* 182(1), 83-91.
 23. Miller CT, Aggarwal S, Lin TK, Dagenais SL, Contreras JI, Orringer MB, Glover TW, Beer DG and Lin L (2003) Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2(DYRK2) gene in esophageal and lung adenocarcinomas. *Cancer Res.* 63, 4136-4143.
 24. Miura I, Graziano SL, Cheng JQ, Doyle LA and Testa JR (1992) Chromosome alterations in human small cell lung cancer: frequent involvement of 5q. *Cancer Res.* 52, 1322-1328.
 25. Miura I, Siegfried JM, Resau J, Keller SM, Zhou J-Y and Testa JR (1990a) Chromosome alterations in 21 non-small cell lung carcinomas. *Genes Chrom. Cancer.* 2, 328-338.
 26. Miura I, Resau J, Tomiyasu T and Testa JR (1990b) Isochromosome (8q) in four patients with adenocarcinoma of the lung. *Cancer Genet. Cytogenet.* 48(2), 203-207.
 27. Mohr LC, Rodgers JK and Silvestri GA (2003) Gultathione S-transferase M1 polymorphism and the risk of lung cancer. *Anticancer Res.* 23(3A), 2111-2124.
 28. Nagayama K, Kohno T, Sato M, Arai Y, Minna JD and Yokota J (2007) Homologous deletion scanning of the lung cancer genome at a 100-kb resolution, *Genes Chrom. Cancer.* 46, 1000-1010.
 29. Rygaard K, Sorenson GD, Pettengill OS, Cate CC, Spang-Thomsen M (1990) Abnormalities in structure and expression of the retinoblastoma gene in small cell lung cancer cell lines and xenografts in nude mice. *Cancer Res.* 50, 5312-4317.
 30. Salido M, Arriola E, Carracedo A, Cañadas I, Rovira A, Espinet B, Rojo F, Arumi M, Serrano S, Albanell J and Sole F (2009) Cytogenetic characterization of NCI-H86 and NCI-H69AR small cell lung cancer cell lines by spectral karyotyping. *Cancer Genet. Cytogenet.* 191(2), 97-101.
 31. Sheilds PG (2002) Molecular epidemiology of smoking and lung cancer. *Oncogene* 21: 6870:6876.
 32. Testa JR, Siegfried JM, Liu Z, Hunt JD, Feder MM, Litwin S, Zhou JY, Taguchi T and Keller SM (1994) Cytogenetic analysis of 63 non-small cell lung carcinomas: recurrent chromosome alterations amid frequent and widespread genomic upheaval. *Genes Chrom. Cancer.* 11(3), 178-194.
 33. Ueda K, Cornwell MM, Gottesman M, Richer IB, Patan I, Roninson IB, Ling V and Riodan JR (1986) The mdr gene responsible for multidrug-resistance, codes for P-glycoprotein. *Biochem. Biophys. Res. Commun.* 141, 956-962.
 34. Nakagawa K, Yokota J, Wada M, Sasaki Y, Fujiwara Y, Sakai M, Muramatsu M, Terasaki T, Tsunokawa Y, Terada M et al., (1988) Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. *Jpn. Cancer Res.* 79, 301-304.
 35. Wang-Peng J, Bunn Jr PA, Kao-Shan CS, Lee EC, Carney DN, Gazdar A and Minna JD (1982) A non-random chromosomal abnormality, del3p(14-23), in human small cell lung cancer(SCLC). *Cancer Genet. Cytogenet.* 6, 119-134.
 36. Wistuba II, Gazdere AF and Minna JD (2001) Molecular genetics of small cell lung carcinoma. *Semi. Oncol.* 2 Suppl. 4, 3-3.
 37. Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, Fujii T and Kitada K (2007) Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. *Cancer Genet. Cytogenet.* 173(1), 1-9.
 38. Yosimura K and Yamashita N (1982) Clinical statistical observation of 4,931 cases with lung cancer by histological types - Results of field study in Japan. *Lung Cancer.* 22(1), 1-16. (In Japanese)
 39. Yuan J, Knorr J., Altmannsberger M, Goeckenjan G, Ahr A., Scharl A and Strebhardt K (1999) Expression of p16 and lack of pRB in primary small cell lung cancer. *J. Pathol.* 189(3), 358-362.
 40. Zabarvsky ER, Lerman MI and Minna JD (2002) Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. *Oncogene.* 21(45), 6915-6935.
 41. Zech L, Bergh J and Nilsson K (1985) Karyotypic characterization of established cell lines and short-term cultures of human lung cancers. *Cancer Genet. Cytogenet.* 15, 335-347.